

Prostate Cancer Practice Insights

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for perirectal spacing have been revised.*

Highlights

- Removal of recommendation that spacers only be used if other techniques for prostate localization and immobilization are insufficient to improve oncologic cure rates and/or reduce side effects (ie, IGRT with CT, ultrasound, implanted fiducials, or electromagnetic targeting/tracking; endorectal balloons).
- Inclusion of Randomized Control Trial Data. ^{1,2,3}
- Inclusion of statement regarding use in patients undergoing brachytherapy
- Specific call-out to biocompatible and biodegradable perirectal spacers

NCCN Guidelines® - Principles of Radiation Therapy PROS-E (1-5)

2020 Update

*"Ideally, the accuracy of treatment should be verified by daily prostate localization, with any of the following: techniques of IGRT using CT, ultrasound, implanted fiducials, or electromagnetic targeting/tracking. Endorectal balloons may be used to improve prostate immobilization. **Biocompatible and biodegradable** perirectal spacer materials may be implanted between the prostate and rectum in patients undergoing external radiotherapy with organ-confined prostate cancer in order to displace the rectum from high radiation dose regions. A **randomized phase III trial demonstrated reduced rectal bleeding** in patients undergoing the procedure compared to controls. **Retrospective data also support its use in similar patients undergoing brachytherapy.***

*Patients with obvious rectal invasion or visible T3 and posterior extension should not undergo perirectal spacer implantation.***

2019

*"Ideally, the accuracy of treatment should be verified by daily prostate localization, with any of the following: techniques of IGRT using CT, ultrasound, implanted fiducials, or electromagnetic targeting/tracking. Endorectal balloons may be used to improve prostate immobilization. **Perirectal spacer materials may be employed when the previously mentioned techniques are insufficient to improve** oncologic cure rates and/or reduce side effects due to anatomic geometry or other patient related factors, such as medication usage and/or comorbid conditions.*

*Patients with obvious rectal invasion or visible T3 and posterior extension should not undergo perirectal spacer implantation.****

* Please refer to the full pdf of the NCCN Guidelines for complete details, available online at [NCCN.org](https://www.nccn.org).

1. Mariados N, Sylvester J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2015 Aug 1;92(5):971-7. <https://pubmed.ncbi.nlm.nih.gov/26054865/>
2. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial. *Int J Radiat Oncol Biol Phys*. 2017 Apr 1;97(5):976-85. 4. <https://pubmed.ncbi.nlm.nih.gov/28209443/>
3. Hamstra DA, Mariados N, Sylvester J, et al. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. *Pract Radiat Oncol*. 2018 Jan - Feb;8(1):e7-e15. <https://pubmed.ncbi.nlm.nih.gov/28951089/>

**Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer, V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed July, 13, 2020. To view the most recent and complete version of the guideline, go to NCCN.org.

***Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2019. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed July, 13, 2020. To view the most recent and complete version of the guideline, go to NCCN.org.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

[SpaceOAR Hydrogel Indications, Safety, and Warnings.](#)

Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752
www.bostonscientific.com

© 2020 Boston Scientific Corporation
or its affiliates. All rights reserved.

URO-815602-AA SEP 2020